Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles

Therapeutic Advances in Psychopharmacology

Volumn 4, Issue 4, 2014, Pages 156-169

  Baumeister, David ^a   Barnes, Georgina ^b   Giaroli, Giovanni ^c   Tracy, Derek ^c  

^a OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NORTH EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

5 HT2A; antidepressants; anxiety; depression; hallucinogen; LSD; psilocybin

Indexed keywords

EID: 84997942146     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125314527985     Document Type: Review

References (82)

1. Aghajanian G. Marek G. (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36: 589–599.
2. Aghajanian G. Marek G. (1999) Serotonin, via 5-HT2A receptors, increases EPSCS in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825: 161–171.
3. Baerentsen K. Stodkilde-Jorgensen H. Sommerlund B. Hartmann T. Damsgaard-Madsen J. Fosnaes M. et al. (2010) An investigation of brain processes supporting meditation. Cogn Process 11: 57–84.
4. Bath K. Akins M. Lee F. (2012) BDNF control of adult SVZ neurogenesis. Dev Psychobiol 54: 578–589.
5. Beique J. Imad M. Mladenovic L. Gingrich J. Andrade R. (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A 104: 9870–9875.
6. Bhattacharyya S. Puri S. Miledi R. Panicker M. (2002) Internalization and recycling of 5-HT2A receptors activated by serotonin and protein kinase C-mediated mechanisms. Proc Natl Acad Sci U S A 99: 14470–14475.
7. Bouso J. Gonzalez D. Fondevila S. Cutchet M. Fernandez X. Ribeiro Barbosa P. et al. (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. PLoS One 7: e42421.
8. Brewer J. Worhunsky P. Gray J. Tang Y. Weber J. Kober H. (2011) Meditation experience is associated with differences in default mode network activity and connectivity. Proc Natl Acad Sci U S A 108: 20254–20259.
9. Brown K. Tracy D. (2013) Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv Psychopharmacol 3: 163–176.
10. Caddy C. Giaroli G. White T. Shergill S. Tracy D. (2014) Ketamine as the prototype glutamatergic antidepressant: pharmacodynamics actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol, in press.
11. Carhart-Harris R. Erritzoe D. Williams T. Stone J. Reed L. Colasanti A. et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109: 2138–2143.
12. Carhart-Harris R. Leech R. Erritzoe D. Williams T. Stone J. Evans J. et al. (2013) Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull 39: 1343–1351.
13. Catlow B. Song S. Paredes D. Kirstein C. Sanchez-Ramos J. (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228: 481–491.
14. Celada P. Bortolozzi A. Artigas F. (2013) Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27: 703–716.
15. Colpaert F. Deseure K. Stinus L. Adriaensen H. (2006) High-efficacy 5-hydroxytryptamine 1a receptor activation counteracts opioid hyperallodynia and affective conditioning. J Pharmacol Exp Ther 316: 892–899.
16. Dantzer R. O’Connor J. Freund G. Johnson R. Kelley K. (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46–56.
17. De Deurwaerdere P. Navailles S. Berg K. Clarke W. Spampinato U. (2004) Constitutive activity of the serotonin2c receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24: 3235–3241.
18. Deakin J. (2013) The origins of ‘5-HT and mechanisms of defence’ by Deakin and Graeff: a personal perspective. J Psychopharmacol, in press.
19. Deakin J. Graeff F. (1991) 5-HT and mechanisms of defence. J Psychopharmacol 5: 305–315.
20. Dowlati Y. Herrmann N. Swardfager W. Liu H. Sham L. Reim E. et al. (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67: 446–457.
21. Dwivedi Y. Mondal A. Payappagoudar G. Rizavi H. (2005) Differential regulation of serotonin (5HT)2A receptor MRNA and protein levels after single and repeated stress in rat brain: role in learned helplessness behavior. Neuropharmacology 48: 204–214.
22. Egan C. Herrick-Davis K. Miller K. Glennon R. Teitler M. (1998) Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl) 136: 409–414.
23. Fjorback L. Arendt M. Ornbol E. Fink P. Walach H. (2011) Mindfulness-based stress reduction and mindfulness-based cognitive therapy: a systematic review of randomized controlled trials. Acta Psychiatr Scand 124: 102–119.
24. Gasser P. Holstein D. Michel Y. Doblin R. Yazar-Klosinski B. Passie T. Brenneisen R. (2014) Safety and efficacy of LSD-assisted psychotherapy in subjects with anxiety associated with life-threatening diseases: a randomized active placebo-controlled phase 2 pilot study. Submitted for publication.
25. Geyer M. Nichols D. Vollenweider F. (2009) Serotonin-related psychedelic drugs. In: Squire L. (ed.), Encyclopedia of Neuroscience. Oxford: Academic Press.
26. Goldapple K. Segal Z. Garson C. Lau M. Bieling P. Kennedy S. et al. (2004) Modulation of cortical–limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 61: 34–41.
27. Gonzalez-Maeso J. Weisstaub N. Zhou M. Chan P. Ivic L. Ang R. et al. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439–452.
28. Gouzoulis-Mayfrank E. Schreckenberger M. Sabri O. Arning C. Thelen B. Spitzer M. et al. (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and D-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20: 565–581.
29. Griffiths R. Richards W. Johnson M. McCann U. Jesse R. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22: 621–632.
30. Griffiths R. Richards W. McCann U. Jesse R. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187: 268–283; discussion 284–292.
31. Grinspoon L. Bakalar J. (1981) The psychedelic drug therapies. Curr Psychiatr Ther 20: 275–283.
32. Grob C. Danforth A. Chopra G. Hagerty M. McKay C. Halberstadt A. et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68: 71–78.
33. Grob C. McKenna D. Callaway J. Brito G. Neves E. Oberlaender G. et al. (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nervous Mental Dis 2: 86–94.
34. Halberstadt A. Geyer M. (2013) Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol 16: 2165–2180.
35. Heisler L. Pronchuk N. Nonogaki K. Zhou L. Raber J. Tung L. et al. (2007) Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J Neurosci 27: 6956–6964.
36. Hofmann S. Sawyer A. Witt A. Oh D. (2010) The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol 78: 169–183.
37. Huxley A. (1954) The Doors of Perception. 1st edn. New York: Harper.
38. Jerome L. (2007) Psilocybin Investigator's Brochure. Multidisciplinary Association for Psychedelic Studies. Available at: http://www.maps.org/research/psilo/psilo_ib.pdf (accessed 3 December 2013).
39. Kennedy S. Evans K. Kruger S. Mayberg H. Meyer J. McCann S. et al. (2001) Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 158: 899–905.
40. Kimura A. Stevenson P. Carter R. MacColl G. French K. Simons J. et al. (2009) Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity. Eur J Neurosci 30: 299–306.
41. Kometer M. Schmidt A. Jancke L. Vollenweider F. (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci 33: 10544–10551.
42. Krebs T. Johansen P. (2013) Psychedelics and mental health: a population study. PLoS One 8: e63972.
43. Krishnan V. Nestler E. (2008) The molecular neurobiology of depression. Nature 455: 894–902.
44. Lanquillon S. Krieg J. Bening-Abu-Shach U. Vedder H. (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22: 370–379.
45. Leslie R. Moorman J. Coulson A. Grahame-Smith D. (1993) Serotonin2/1c receptor activation causes a localized expression of the immediate–early gene C-Fos in rat brain: evidence for involvement of dorsal Raphe nucleus projection fibres. Neuroscience 53: 457–463.
46. MacLean K. Johnson M. Griffiths R. (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.
47. Mendelson S. (2000) The current status of the platelet 5-HT(2A) receptor in depression. J Affect Disord 57: 13–24.
48. Millan M. Marin P. (2008) Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 29: 454–464.
49. Moreno F. Wiegand C. Taitano E. Delgado P. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive–compulsive disorder. J Clin Psychiatry 67: 1735–1740.
50. Moreno J. Holloway T. Albizu L. Sealfon S. Gonzalez-Maeso J. (2011) Metabotropic glutamate MGLU2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 493: 76–79.
51. Murray R. Paparelli A. Morrison P. Marconi A. Di Forti M. (2013) What can we learn about schizophrenia from studying the human model, drug-induced psychosis? Am J Med Gen B: Neuropsych Gen 162: 661–670.
52. Nichols C. Sanders-Bush E. (2002) A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 26: 634–642.
53. Nichols D. (2004) Hallucinogens. Pharmacol Ther 101: 131–181.
54. Nutt D. King L. Nichols D. (2013) Effects of schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci 14: 577–585.
55. Nutt D. King L. Phillips L. (2010) Drug harms in the UK: a multicriteria decision analysis. Lancet 376: 1558–1565.
56. Ohira K. Takeuchi R. Shoji H. Miyakawa T. (2013) Fluoxetine-induced cortical adult neurogenesis. Neuropsychopharmacology 38: 909–920.
57. Pandey G. Dwivedi Y. Rizavi H. Ren X. Pandey S. Pesold C. et al. (2002) Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 159: 419–429.
58. Paul E. Lowry C. (2013) Functional topography of serotonergic systems supports the Deakin/Graeff hypothesis of anxiety and affective disorders. J Psychopharmacol 27: 1090–1106.
59. Pei Q. Lewis L. Sprakes M. Jones E. Grahame-Smith D. Zetterstrom T. (2000) Serotonergic regulation of MRNA expression of ARC, an immediate early gene selectively localized at neuronal dendrites. Neuropharmacology 39: 463–470.
60. Pandey G.N. Dwivedi Y. Ren X. Rizavi H.S. Faludi G. Sarosi A. Palkovits M. (2006) Regional distribution and relative abundance of serotonin (2c) receptors in human brain: effect of suicide. Neurochem Res 31: 167–76.
61. Penn E. Tracy D. (2012) The drugs don't work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2: 179–188.
62. Presti D.E. Nichols. (2004) Biochemistry and neuropharmacology of psilocybin mushrooms. In: Metzner R. Darling D.C. (eds) Teonanacatl. Four Trees, El Verano, CA, pp 89–108.
63. Raote I. Bhattacharyya S. Panicker M. (2013) Functional selectivity in serotonin receptor 2A (5-HT2A) endocytosis, recycling, and phosphorylation. Mol Pharmacol 83: 42–50.
64. Rosenzweig-Lipson S. Sabb A. Stack G. Mitchell P. Lucki I. Malberg J. et al. (2007) Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist way-163909 in rodents. Psychopharmacology (Berl) 192: 159–170.
65. Roth B. Palvimaki E. Berry S. Khan N. Sachs N. Uluer A. et al. (1995) 5-hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther 275: 1638–1646.
66. Santarelli L. Saxe M. Gross C. Surget A. Battaglia F. Dulawa S. et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805–809.
67. Savitz J. Lucki I. Drevets W. (2009) 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol 88: 17–31.
68. Sen S. Duman R. Sanacora G. (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64: 527–532.
69. Shelton R. Sanders-Bush E. Manier D. Lewis D. (2009) Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 158: 1406–1415.
70. Studerus E. Kometer M. Hasler F. Vollenweider F. (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25: 1434–1452.
71. Tracy D. Shergill S. (2013) Mechanisms underlying auditory hallucinations—understanding perception without stimulus. Brain Sci 3: 642–669.
72. United Nations (1971) Convention on Psychotropic Substances. Available at: http://www.unodc.org/pdf/convention_1971_en.pdf (accessed 3 December 2013).
73. Vitalis T. Ansorge M. Dayer A. (2013) Serotonin homeostasis and serotonin receptors as actors of cortical construction: special attention to the 5-HT3A and 5-HT6 receptor subtypes. Front Cell Neurosci 7: 93.
74. Vollenweider F. Kometer M. (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11: 642–651.
75. Vollenweider F. Leenders K. Scharfetter C. Maguire P. Stadelmann O. Angst J. (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357–372.
76. Vollenweider F. Vollenweider-Scherpenhuyzen M. Babler A. Vogel H. Hell D. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897–3902.
77. Wacker D. Wang C. Katritch V. Han G. Huang X. Vardy E. et al. (2013) Structural features for functional selectivity at serotonin receptors. Science 340: 615–619.
78. Wang C. Jiang Y. Ma J. Wu H. Wacker D. Katritch V. et al. (2013) Structural basis for molecular recognition at serotonin receptors. Science 340: 610–614.
79. Weisstaub N. Zhou M. Lira A. Lambe E. Gonzalez-Maeso J. Hornung J.P. et al. (2006) Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 313: 536–540.
80. Whitfield-Gabrieli S. Ford J. (2012) Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol 8: 49–76.
81. Yu B. Becnel J. Zerfaoui M. Rohatgi R. Boulares A. Nichols C. (2008) Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 327: 316–323.
82. Zunszain P. Anacker C. Cattaneo A. Choudhury S. Musaelyan K. Myint A. et al. (2012) Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37: 939–949.